

Annamaria Gulla

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9368784/annamaria-gulla-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30
papers

1,501
citations

16
h-index

32
g-index

32
ext. papers

1,708
ext. citations

4.7
avg, IF

4.07
L-index

#	Paper	IF	Citations
30	Targeting Free Light Chain Secretion Via Botulinum Neurotoxin Is a Novel Therapeutic Strategy in AL Amyloidosis By Inducing a Terminal Unfolded Protein Response. <i>Blood</i> , 2021 , 138, 1576-1576	2.2	1
29	Dual BCL-2/BCL-XL Inhibitor Pelcitoclax (APG-1252) Overcomes Intrinsic and Acquired Resistance to Venetoclax in Multiple Myeloma Cells. <i>Blood</i> , 2021 , 138, 2655-2655	2.2	1
28	Identifying Long Noncoding RNA Dependencies Using CRISPR Interference (CRISPRi)-Based Platform in Multiple Myeloma. <i>Blood</i> , 2021 , 138, 894-894	2.2	
27	Gabarap Loss Mediates Immune Escape in High Risk Multiple Myeloma. <i>Blood</i> , 2021 , 138, 891-891	2.2	1
26	ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment. <i>Blood Cancer Discovery</i> , 2021 , 2, 338-353	7	1
25	Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. <i>Blood Cancer Discovery</i> , 2021 , 2, 468-483	7	15
24	The Non-Coding RNA Landscape of Plasma Cell Dyscrasias. <i>Cancers</i> , 2020 , 12,	6.6	14
23	RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 20-21	2.2	
22	Multiple myeloma: the (r)evolution of current therapy and a glance into future. <i>Haematologica</i> , 2020 , 105, 2358-2367	6.6	21
21	Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities. <i>Frontiers in Oncology</i> , 2020 , 10, 606368	5.3	7
20	Targeting Myeloma Cell Metabolism Via Disruption of the Lnc-17-92 Transcriptional Program: Druggable New Vulnerability in Multiple Myeloma. <i>Blood</i> , 2019 , 134, 317-317	2.2	1
19	The Transmembrane Receptor Roundabout 1 (ROBO1) Is Necessary for Multiple Myeloma Proliferation and Homing to the Bone Marrow Niche. <i>Blood</i> , 2019 , 134, 507-507	2.2	
18	Loss-of-Function of Gabarap Impairs Bortezomib-Induced Anti-Tumor Immunity in Multiple Myeloma: Clinical Application. <i>Blood</i> , 2019 , 134, 134-134	2.2	2
17	Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. <i>Leukemia</i> , 2018 , 32, 2626-2635	10.7	31
16	Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92. <i>Blood</i> , 2018 , 132, 1050-1063	2.2	40
15	Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. <i>Blood</i> , 2017 , 129, 2233-2245	2.2	25
14	Mir-221/222 are promising targets for innovative anticancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2016 , 20, 1099-108	6.4	36

13	A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. <i>Clinical Cancer Research</i> , 2016 , 22, 1222-33	12.9	79
12	Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts. <i>Oncotarget</i> , 2015 , 6, 27343-58	3.3	78
11	Identification of a Novel Long Intergenic Noncoding RNA - Linc00936, with Significant Impact on Multiple Myeloma Cell Growth Via mTOR Pathway Inhibition. <i>Blood</i> , 2015 , 126, 504-504	2.2	2
10	Mir-34: a new weapon against cancer?. <i>Molecular Therapy - Nucleic Acids</i> , 2014 , 3, e194	10.7	358
9	Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities. <i>Frontiers in Oncology</i> , 2014 , 4, 348	5.3	48
8	Transferrin-conjugated SNALPs encapsulating 2'UO-methylated miR-34a for the treatment of multiple myeloma. <i>BioMed Research International</i> , 2014 , 2014, 217365	3	38
7	In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells. <i>PLoS ONE</i> , 2014 , 9, e89659	3.7	72
6	In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. <i>PLoS ONE</i> , 2014 , 9, e90005	3.7	90
5	Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. <i>Oncotarget</i> , 2014 , 5, 3039-54	3.3	80
4	Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. <i>Clinical Cancer Research</i> , 2013 , 19, 2096-106	12.9	165
3	In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. <i>Oncotarget</i> , 2013 , 4, 242-55	3.3	109
2	Inhibition Of Mir-21 In HS-5 Bone Marrow Stromal Cells In The Presence Of Multiple Myeloma cells Restores RANKL/OPG Ratio: A Potential Therapeutic Approach For Myeloma-Related Bone Disease. <i>Blood</i> , 2013 , 122, 683-683	2.2	
1	Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. <i>Clinical Cancer Research</i> , 2012 , 18, 6260-70	12.9	185